Adjuvant Aflibercept for Metastatic Colorectal Cancer (C261)
BrUOG C261:Single Agent Adjuvant Aflibercept for Patients With Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study
Sponsor: Brown University
Terminated
Lack of efficacy and enrollment
Other terminated trials from Brown University
Other Metastatic Colorectal Cancer trials with similar outcome
A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Brown University and has accumulated 11 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2019 — Mar 2020 [monthly]
Terminated PHASE2
-
Jul 2018 — May 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brown University
- Lifespan
- Montefiore Medical Center
- Rhode Island Hospital
- Sanofi
- The Miriam Hospital
- University of California, San Diego
- University of Florida
For direct contact, visit the study record on ClinicalTrials.gov .